SEC Form 424B3 filed by Jupiter Neurosciences Inc.
$JUNS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
Investigational Oral Candidate JOTROL™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson's Disease (PD), with first patient dosing expected in the near term. Parkinson's Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering"). "Yesterday's capital raise helps the Company p
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions. T
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th